#ASH22: Bristol Myers reports next-gen CAR-T data as rival’s bispecific heads to FDA, and gives alnuctamab another shot

NEW ORLEANS — Bristol Myers Squibb pulled back the curtain on its CAR-T cell therapy going after GPRC5D, and also released Phase I data for …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ASH22: Bris­tol My­ers re­ports next-gen CAR-T da­ta as ri­val’s bis­pe­cif­ic heads to FDA, and gives al­nuc­tam­ab an­oth­er shot